Do you want to read an article? Please log in or register.
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
Breast Cancer
Related content
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
Lung, Respiratory and Thoracic Cancer
Treatment outcome of NSCLC patients with BRAF(non-V600E) mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
ESMO Open
Kropf-Sanchen C, Rasokat A, Christopoulos P, Wenzel C, Wehler T, Rost M, Kulhavy J, Reinmuth N, Schulz C, Scheffler M, Wolf J, Büttner R, Merkelbach-Bruse S, Thomas M, Stenzinger A, Schütz M, Bräuninger A, Demes M, Hummel HD, Pfarr N, Gaisa NT, Rawluk J, Berezucki E, Lutz KT, Galda S, Jacobi H, Collienne M, Janning M, Brummer T, Loges S, nNGM Lung Cancer
doi: 10.1016/j.esmoop.2025.105124
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
Lung, Respiratory and Thoracic Cancer
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials
J Clin Oncol
Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC
doi: 10.1200/JCO-24-01579
Breast Cancer
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial
J Natl Cancer Inst
Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS
doi: 10.1093/jnci/djae268
Breast Cancer
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
Int J Cancer
García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D
doi: 10.1002/ijc.35432
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
COMMENTED
Breast Cancer
Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer
★ 0
Recommended and commented by
Dr Andreas Müller, Faculty Member
Clin Breast Cancer
Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK)
doi: 10.1016/j.clbc.2025.05.015
Breast Cancer
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Eur J Cancer
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L
doi: 10.1016/j.ejca.2024.115113